The Cannabis ETF (THCX)
ARCA ARCA Primary 
Cannabis Stocks To Watch Ahead Of September 2024
Cannabis stocks to watch right now.
Cannabis Stocks Plummet By Up To 16% On DEA Rescheduling Delay: Could This Be The Buying Opportunity Of 2024?
The U.S. Drug Enforcement Administration (DEA) announced a delay on Monday in its final ruling on cannabis rescheduling until after the November presidential election. The decision, which has created uncertainty in the market, pits Vice President Kamala Harris, a cannabis reform advocate, against former President Donald Trump, whose vice-presidential pick is opposed to legalization.
High-Growth Cannabis Stocks: Momentum Plays to Watch Right Now
The US cannabis industry continues to grow, offering investors opportunities in the marijuana penny stock sector. As of 2024, the US cannabis market is projected to reach $41 billion, driven by increasing legalization efforts across states. Recent news about potential federal legalization has further boosted investor optimism, making this a crucial time to identify promising stocks. However, investing in penny stocks carries inherent risks due to their volatility. Therefore, it's essential to approach these investments with caution. Using technical analysis, investors can identify patterns and trends, which helps make informed decisions. Moreover, proper risk management strategies, like setting stop-loss orders, can minimize potential losses.
CBD Life Sciences, Inc. Expands Footprint With Proposed Strategic Acquisition of Interest in Two New York Cannabis Dispensaries
The targeted acquisitions are estimated to have a business value of approximately $14 million SCOTTSDALE, AZ / ACCESSWIRE / August 27, 2024 / CBD Life Sciences, Inc. (OTC PINK:CBDL), a leading innovator in the CBD industry, is pleased to announce that the company is in advanced discussions to acquire a strategic minority interest in two state-licensed cannabis dispensaries located in Upstate New York and Long Island. This acquisition represents a significant growth milestone for CBD Life Sciences, Inc. as the company continues to expand its presence in the rapidly growing cannabis market.
Prediction: Aurora Cannabis Will Be Worth More Than Canopy Growth in 5 Years
Aurora Cannabis and Canopy Growth have been leading companies within the cannabis industry for years. Both businesses have struggled, however, and have been working on improving their financials.
Gold Flora's Q2: A Mixed Bag For Cannabis With EBITDA Down $2M, Margins Up To 57%
Gold Flora GRAM reported Q2 2024 sales of $31.6 million, marking a 2% sequential decline and falling short of the estimated $34.2 million. According to a report by Zuanic & Associates, the performance of the Californian cannabis company raised concerns despite a generally positive medium-term outlook.
NewLake Capital: Lock In Yields As Cannabis Federal Rescheduling Likely Near
NLCP has outperformed expectations again, with robust FQ2'24 performance as its tenants' profitability continues to improve. Thanks to the expanding bottom-line and tighter share count, it is unsurprising that the cannabis REIT's AFFO per share has recorded a double-digit YoY growth. With the two presidential candidates' stances rather dovish and the Justice Department submitting the Proposed Regulation to Reschedule Marijuana, sentiments have lifted dramatically indeed.
Top Canadian Cannabis Stocks to Watch Now: High-Growth Opportunities in 2024
The Canadian cannabis market continues to play a pivotal role in the North American cannabis industry. As US cannabis laws evolve, Canadian companies are well-positioned to capitalize on this growth. The US cannabis industry is expected to reach $45.9 billion by 2025, driven by increased legalization and consumer demand. Recent headlines have highlighted ongoing discussions in Congress about federal legalization, which could be a game-changer. With more states moving toward legalization, the market is ripe for expansion. Canadian cannabis stocks are gaining attention as investors look for opportunities in this growing sector. These stocks offer exposure to the Canadian market and the potential US boom.
Aurora Cannabis Had a Strong Q1, but Investors Should Expect a Slowdown in Future Quarters
Aurora Cannabis has made significant strides in improving its financials. The company generated positive free cash flow and revenue rose last quarter.
Top Cannabis REITs to Watch in Mid-August: Maximizing Growth and Dividends
As the U.S. cannabis industry continues its rapid expansion, cannabis-focused REITs (Real Estate Investment Trusts) are becoming essential investment vehicles. The industry is projected to grow significantly, with sales expected to reach $41 billion by 2025. This growth is driven by increasing state-level legalization and a rising number of cannabis operators. Recently, headlines have speculated about potential federal legalization, which could further accelerate the industry's expansion. Investors are now keenly watching cannabis REITs, which provide the critical real estate infrastructure needed for cultivation, processing, and retail operations. These REITs offer a unique opportunity to capitalize on the industry's growth while managing risk through diversified portfolios. Furthermore, many cannabis REITs pay attractive dividends, adding a steady income stream to their growth potential.
Cannabis MSOs embrace new markets, streamline operations in Q2
Earnings from North American cannabis companies for the second quarter have been a mixed bag, with expansion into new markets, operational streamlining, and product innovation key themes across the sector. Many multi-state operations (MSOs) are turning to emerging, less saturated international markets for growth, notably, Germany, which kicked off expanded medical sales amid broader legalization measures on April 1.
Cannabis Rescheduling Likely 'In The Next 12 Months,' Says MariMed CEO As Company Invests In Key Markets
Senior analyst Pablo Zuanic hosted a fireside chat Monday evening with Jon Levine, CEO of MariMed Inc. MRMD who outlined the company's operations, growth strategies and financial outlook. The discussion provided insights into MariMed's performance in key states as well as expansion plans and future projections, offering valuable information for cannabis investors.
